The most effective treatment for clinically limited prostate cancer (T1-2) is radical prostatectomy (also known as radical prostate cancer surgery). There has been controversy as to whether radical surgery is appropriate for clinically advanced prostate cancer (T3) without distant metastases. It is generally believed that radical prostatectomy does not completely control locally advanced prostate cancer and does not improve the long-term survival of these patients. A large number of clinical studies have shown that many patients with locally advanced prostate cancer survive or are cured after radical surgery. In the symposium on prostate cancer at the 18th National Urology Symposium on October 29, 2011, urologists from Europe and China presented new perspectives on the treatment of locally advanced prostate cancer and discussed extensively the new contents of the 2011 European Guidelines for the Management of Prostate Cancer and the 2011 Chinese Guidelines for the Management of Prostate Cancer. The results of this study were that radical surgery is an option for locally advanced prostate cancer, and that radical surgery can lead to a cure for many clinically advanced prostate cancers. Neoadjuvant endocrine therapy compared with surgery alone can reduce the rate of positive surgical margins, reduce tumor stage, reduce the rate of positive regional lymph nodes, and reduce the rate of local recurrence of cT2 stage tumors, but not significantly reduce the rate of local recurrence of cT3 stage tumors. It cannot improve seminal vesicle infiltration, and has no significant improvement on biochemical recurrence-free survival and overall survival, pending longer follow-up. The impact on surgery is not significant. With this approach, many patients with locally advanced disease have been cured. Especially nowadays, minimally invasive surgery (laparoscopic radical prostate cancer surgery) has been adopted, which is easier, less invasive and faster recovery. The most effective treatment for clinically limited prostate cancer (T1-2) is radical prostatectomy (also known as radical prostate cancer surgery). Whether radical surgery is appropriate for clinically advanced prostate cancer (T3) without distant metastases has been controversial. It is generally believed that radical prostatectomy does not completely control locally advanced prostate cancer and does not improve the long-term survival of these patients. A large number of clinical studies have shown that many patients with locally advanced prostate cancer survive or are cured after radical surgery. In the symposium on prostate cancer at the 18th National Urology Symposium on October 29, 2011, urologists from Europe and China presented new perspectives on the treatment of locally advanced prostate cancer and discussed extensively the new contents of the 2011 European Guidelines for the Management of Prostate Cancer and the 2011 Chinese Guidelines for the Management of Prostate Cancer. The results of this study were that radical surgery is an option for locally advanced prostate cancer, and that radical surgery can cure many clinically advanced prostate cancers. The neoadjuvant endocrine therapy of the Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, China, compared with surgery alone, can reduce the rate of positive surgical margins, tumor stage, regional lymph node positivity, and local recurrence of cT2 stage tumors, but not significantly reduce the local recurrence of cT3 stage tumors. It cannot improve seminal vesicle infiltration, and has no significant improvement on biochemical recurrence-free survival and overall survival, pending longer follow-up. The impact on surgery is not significant. With this approach, many patients with locally advanced disease have been cured. Especially nowadays, minimally invasive surgery (laparoscopic radical prostate cancer treatment) is adopted, which is easier, less invasive and faster recovery.